Annals of dermatology最新文献

{"title":"Updates in Dermatomyositis: Newer Treatment Options and Outcome Measures From Dermatologic Perspectives.","authors":"Hee Joo Kim, Victoria P Werth","doi":"10.5021/ad.24.022","DOIUrl":"10.5021/ad.24.022","url":null,"abstract":"<p><p>Dermatomyositis (DM) is a rare autoimmune connective tissue disease with characteristic skin manifestations and possible muscle involvement. Recent advances in classification system to include skin-predominant subtypes, understanding underlying pathogenic mechanisms and the relationship between clinical phenotypes and myositis-specific autoantibodies have led to development of novel therapeutic options. This corresponds with efforts to develop better outcome measures to accurately catch the patients' current disease status and treatment-induced improvements. This report will review the updates in newer treatments and outcome measures of DM, specifically from a dermatologic point of view.</p>","PeriodicalId":94298,"journal":{"name":"Annals of dermatology","volume":"36 5","pages":"257-265"},"PeriodicalIF":0.0,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11439981/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142335693","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Randomized, Split-Face, Comparative Study of a Combined Needle Radiofrequency/Intense Pulsed Light Device in Moderate-to-Severe Acne Patients.","authors":"Ki Yeon Kim, Seon Young Song, You Jin Jung, Mihn Sook Jue, Ji Yeon Hong, Beom Joon Kim, Joo Yeon Ko","doi":"10.5021/ad.23.083","DOIUrl":"10.5021/ad.23.083","url":null,"abstract":"<p><strong>Background: </strong>Radiofrequency (RF) and intense pulsed light (IPL) have been reported as efficient adjuvant treatment modalities for acne vulgaris.</p><p><strong>Objective: </strong>We sought to evaluate the clinical efficacy and safety of a combined needle RF and vacuum IPL device for acne treatment without the use of other conventional topical or oral agents.</p><p><strong>Methods: </strong>This randomized, split-faced study was designed to include patients with moderate to severe acne vulgaris. Comedone extraction was performed on both parts of the face prior to laser treatment. One side of the face was treated with RF and IPL in 2-week intervals, while the other side was left untreated as a control. Two independent blinded investigators evaluated the patients for improvement using clinical photographs. We also assessed for possible adverse effects.</p><p><strong>Results: </strong>The study included 44 patients with acne vulgaris (27 men and 17 women). Their ages ranged from 19-39 years (average, 23 years). At the final 12-week follow-up visit, the acne reduction rate was 34.80% (±33.45%; range, 30.92%-19.03%) on the treated side and 13.76% (±37.58%; range, 28.26%-23.27%) in the control group compared to baseline, constituting a significant difference. The difference in reduction rate between the treated and control sides was 21.03% (±25.09%), with the treated side experiencing more significant improvement (<i>p</i><0.05). In the assessment of adverse events, one patient experienced mild surrounding erythema that spontaneously improved.</p><p><strong>Conclusion: </strong>Combined treatment of needle RF and IPL could improve acne lesions.</p>","PeriodicalId":94298,"journal":{"name":"Annals of dermatology","volume":"36 5","pages":"266-274"},"PeriodicalIF":0.0,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11439985/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142335685","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Similar Seasonality in Childhood-Onset, Pediatric, and Adulthood-Onset Vitiligo: A Common Data Model Analysis of 16 Real-World Databases.","authors":"Yun-Ji Lee, Yoonsung Lee, Man S Kim, Bark-Lynn Lew, Soon-Hyo Kwon","doi":"10.5021/ad.23.076","DOIUrl":"10.5021/ad.23.076","url":null,"abstract":"","PeriodicalId":94298,"journal":{"name":"Annals of dermatology","volume":"36 5","pages":"326-328"},"PeriodicalIF":0.0,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11439979/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142335690","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploring the Interplay: Obesity, Lipid Metabolism, and Clinical Manifestations in Atopic Dermatitis.","authors":"Howard Chu, Yeon Woo Jung, Su Min Kim, Byung Gi Bae, Jung Min Bae, Lark Kyun Kim, Kwang Hoon Lee, Chang Ook Park","doi":"10.5021/ad.23.151","DOIUrl":"10.5021/ad.23.151","url":null,"abstract":"<p><strong>Background: </strong>The interest toward the association between atopic dermatitis (AD) and obesity is increasing, yet the possibility of abnormal lipid metabolism has never been investigated before.</p><p><strong>Objective: </strong>To identify the characteristics of patients with AD who are obese and analyze the serum lipid profiles of these patients.</p><p><strong>Methods: </strong>This observational study included 167 patients diagnosed with AD and underwent evaluations for serum lipid panels between July 2017 and October 2017. The patients' body mass index was used to determine obesity and the serum lipid panels were analyzed between patients who are obese and non-obese. Also, the disease severity and subjective symptoms were evaluated and serum total immunoglobulin E (IgE) and specific IgE levels were assessed.</p><p><strong>Results: </strong>Of the 167 patients with AD, there were 36 obese and 131 non-obese subjects. Obese patients were found to have a significantly higher disease severity, as well as higher serum triglyceride and low-density lipoprotein-cholesterol levels and lower high-density lipoprotein-cholesterol levels, which was most pronounced in adult males. Obesity AD patients also had a significantly higher serum total IgE, itch intensity score, and number of allergens sensitized.</p><p><strong>Conclusion: </strong>Patients with AD who are obese should be monitored for possible abnormalities in lipid metabolism. Obesity may be a factor that contributes to a higher disease severity of AD.</p>","PeriodicalId":94298,"journal":{"name":"Annals of dermatology","volume":"36 5","pages":"310-317"},"PeriodicalIF":0.0,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11439982/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142335688","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Plasma Metabolomics Indicates Potential Biomarkers and Abnormal Metabolic Pathways in Female Melasma Patients.","authors":"Xiaoli Zhang, Yi Chen, Hedan Yang, Hui Ding, Pingping Cai, Yiping Ge, Huiying Zheng, Xiaojie Sun, Yin Yang, Xinyu Li, Tong Lin","doi":"10.5021/ad.23.141","DOIUrl":"10.5021/ad.23.141","url":null,"abstract":"<p><strong>Background: </strong>Melasma is a common and chronic pigmentary disorder with complex pathogenesis, and the relationship between melasma and metabolic syndrome remains elusive. Thus, metabolomics might contribute to the early detection of potential metabolic abnormalities in individuals with melasma.</p><p><strong>Objective: </strong>The present study aims to analyze changes in plasma metabolites of female melasma patients and identify disease markers as well as explore potential therapeutic targets.</p><p><strong>Methods: </strong>Plasma samples from 20 female patients with melasma and 21 healthy female controls that were comparable in terms of age and body mass index were collected for untargeted metabolomics investigations. Ultra-high performance liquid chromatography-mass spectrometry was used to analyze metabolites in the plasma. Metabolic pathway analyses were employed to identify significantly differentially expressed metabolites in melasma patients. Receiver operating characteristic curves were constructed, and correlation analyses were performed using the modified Melasma Area and Severity Index and oxidative stress levels.</p><p><strong>Results: </strong>In contrast to healthy subjects, melasma patients showed significant alterations in 125 plasma metabolites, including amino acids, lipids, and carbohydrate-related metabolites. KEGG pathway analysis suggested that primary pathways associated with the development of melasma include tryptophan metabolism, as well as the biosynthesis of phenylalanine, tyrosine, and tryptophan. Importantly, based on receiver operating characteristic curves and correlation analyses, several metabolites were identified as robust biomarkers for melasma.</p><p><strong>Conclusion: </strong>Collectively, this study identified significant changes in plasma metabolites in melasma patients, providing new insights into the pathogenesis of melasma and opening novel therapeutic avenues.</p>","PeriodicalId":94298,"journal":{"name":"Annals of dermatology","volume":"36 5","pages":"300-309"},"PeriodicalIF":0.0,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11439978/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142335689","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Factors Affecting the Response and Patient Satisfaction of Topical Immunotherapy in Alopecia Areata: A Nationwide Study.","authors":"Young Lee, Kyungmin Kim, Bark-Lynn Lew, Chang-Hun Huh, Hoon Kang, Yong Hyun Jang, Do Young Kim, Hyun-Tae Shin, Moon-Bum Kim, Jin Park, Min Sung Kim, Gwang Seong Choi","doi":"10.5021/ad.23.138","DOIUrl":"10.5021/ad.23.138","url":null,"abstract":"<p><strong>Background: </strong>Contact immunotherapy using diphenylcyclopropenone (DPCP) is a recommended treatment for severe alopecia areata (AA); however, few clinical factors are known, and few standardized application methods affecting therapeutic efficacy have been devised.</p><p><strong>Objective: </strong>To confirm the therapeutic response of DPCP immunotherapy in AA, first we analyze the factors influencing its outcome and patient satisfaction levels, after which we standardize the DPCP treatment method for better outcomes.</p><p><strong>Methods: </strong>We utilized a nationwide questionnaire-based survey to assess patient satisfaction and undertook a medical record review involving 412 patients currently undergoing treatment for DPCP.</p><p><strong>Results: </strong>The patients' mean age was 36.4 years, and 27% of the cases were diagnosed as AA in childhood. Treatment response was higher when DPCP was used to treat the entire scalp, including subclinical lesions, and longer treatment durations and longer intervals between treatments were associated with a better treatment response. Atopy (atopic dermatitis, allergic rhinitis and bronchial asthma), thyroid disorder, and extent of hair loss were all negatively correlated with the treatment response. However, there was no correlation between the treatment response and factors such as the age of onset, a family history of AA, nail changes, or AA duration, which are commonly known to be associated with a poor prognosis.</p><p><strong>Conclusion: </strong>DPCP immunotherapy is an effective treatment for AA, and the study demonstrated the factors affecting DPCP treatment response and patients' satisfaction and may contribute to standardizing the DPCP treatment method for better outcomes.</p>","PeriodicalId":94298,"journal":{"name":"Annals of dermatology","volume":"36 4","pages":"225-230"},"PeriodicalIF":0.0,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11291100/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141857530","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Nail Psoriasis: Clinical Features and Severity Assessment.","authors":"Sang Woong Youn","doi":"10.5021/ad.24.026","DOIUrl":"10.5021/ad.24.026","url":null,"abstract":"<p><p>The nail is an important characteristic in the context of psoriasis. Nail psoriasis exhibits several clinical manifestations. Since the development of the Nail Psoriasis Severity Index (NAPSI) score assessment tool for evaluating the severity of nail psoriasis, nail matrix symptoms such as pitting, leukonychia, crumbling, and red spots have been observed in the lunula. Nail bed symptoms include onycholysis, subungual hyperkeratosis, oil spots, and splinter hemorrhage. However, Beau's lines and nail fold psoriasis, which are not included in this assessment tool, should be considered essential symptoms for indicating the activity of nail psoriasis. Although NAPSI is the most widely used tool for assessing the severity of nail psoriasis, it has uncontrolled limitations. Although other assessment tools have been developed, none have successfully replaced the NAPSI. In clinical trials for nail psoriasis, the NAPSI is used in various forms, such as improvement rates, changes in the mean NAPSI score, and achievement rates of NAPSI 75. Consequently, caution is warranted when interpreting the clinical trial results related to nail psoriasis improvement.</p>","PeriodicalId":94298,"journal":{"name":"Annals of dermatology","volume":"36 4","pages":"191-196"},"PeriodicalIF":0.0,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11291102/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141857533","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Up-and-Coming Drugs for the Treatment of Vitiligo.","authors":"Seol Hwa Seong, Sang Ho Oh","doi":"10.5021/ad.24.038","DOIUrl":"10.5021/ad.24.038","url":null,"abstract":"<p><p>Vitiligo is a chronic autoimmune disease that causes depigmented patches on the skin. It affects 0.5%-2.0% of the global population. It goes beyond physical appearance, often leading to stigmatization, low self-esteem, and depression, burdening patients with psychosocial challenges. The pathogenesis of vitiligo involves the loss of melanocytes due to autoreactive CD8+ T cells, triggered by environmental stressors and exacerbated by cellular vulnerabilities and immune responses. The release of danger signals and pro-inflammatory factors initiates an immune cascade perpetuating melanocyte destruction, mainly driven by interferon-γ and the C-X-C motif chemokine ligand 9/10-chemokine receptor 3 axis. Long-lasting tissue-resident memory T cells (Trms) and cytokines contribute to lesion persistence. Current treatments focus on topical steroids and tacrolimus, systemic steroids, and phototherapies, but their efficacy remains suboptimal, necessitating the development of new therapeutic options. Building on recent advancements in understanding the immunological mechanisms in vitiligo pathogenesis, with the initiation of Food and Drug Administration approval of topical ruxolitinib, various potential treatment options such as JAK inhibitors, cytokine blockers, and Trm or regulatory T cell targeting agents are being clinically researched and anticipated for vitiligo based on both preclinical and clinical data. This review aims to categorize and summarize the diverse investigational drugs currently undergoing clinical trials for vitiligo. By examining clinical outcomes, it is anticipated that this review will bring hope to dermatologists and patients regarding vitiligo, a condition that has historically posed challenges and transform it into a realm of potential possibilities.</p>","PeriodicalId":94298,"journal":{"name":"Annals of dermatology","volume":"36 4","pages":"197-208"},"PeriodicalIF":0.0,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11291099/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141857536","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Intralesional Methotrexate Injection for the Treatment of Epithelial Crateriform Tumor.","authors":"Jun Hyuk Cho, Hyun Mo Lee, Yoon Jae Kim, Dai Hyun Kim, Hyo Hyun Ahn, Soo Hong Seo","doi":"10.5021/ad.23.135","DOIUrl":"10.5021/ad.23.135","url":null,"abstract":"<p><strong>Background: </strong>Intralesional methotrexate injection (IL-MTX) is an appropriate strategy for treating epithelial crateriform tumors (ECTs) when surgical excision can result in functional or cosmetic defects; however, not all ECTs are responsive to this treatment.</p><p><strong>Objective: </strong>This study aimed to evaluate the effectiveness of IL-MTX for ECTs and to determine the differences in clinical response according to the pathological features.</p><p><strong>Methods: </strong>The medical records of patients treated with IL-MTX for their ECTs were retrospectively reviewed. Effectiveness was evaluated in terms of size reduction and flattening.</p><p><strong>Results: </strong>Twenty-five cases of ECTs with biopsy were included in this study. Eight cases of keratoacanthoma (KA) and 15 cases of squamous cell carcinoma (SCC) were identified, but 2 cases could not be clearly distinguished. Seventeen patients (68%) showed a response after injection, and response rate in KA and SCC were 75% (6/8) and 60% (9/15), respectively. Nine patients showed complete resolution with IL-MTX. Patients received 3 injections, and regression was observed in 7.56 weeks after the first injection. According to histopathological results, patients with KA and SCC received 2 and 3.33 injections, respectively, and complete resolution was observed after 7 and 7.67 weeks, respectively.</p><p><strong>Conclusion: </strong>IL-MTX is safe and effective, and could be considered as a useful non-surgical treatment option for ECTs. Both KA and crateriform SCC showed good response; However, KA showed a better response.</p>","PeriodicalId":94298,"journal":{"name":"Annals of dermatology","volume":"36 4","pages":"209-214"},"PeriodicalIF":0.0,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11291104/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141857531","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Retraction: Review of Scoring Systems for Hidradenitis Suppurativa.","authors":"Youngbeom Kim, Jungsoo Lee, Hoon-Soo Ki, Hyun-Chang Ko, Byung-Soo Kim, Moon-Bum Kim, Kihyuk Shin","doi":"10.5021/ad.36.001","DOIUrl":"10.5021/ad.36.001","url":null,"abstract":"","PeriodicalId":94298,"journal":{"name":"Annals of dermatology","volume":"36 4","pages":"255"},"PeriodicalIF":0.0,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11291103/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141857534","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}